CO6321135A2 - Modulares canabinoides de tetrahidrotiopirano pirazol - Google Patents

Modulares canabinoides de tetrahidrotiopirano pirazol

Info

Publication number
CO6321135A2
CO6321135A2 CO07109275A CO07109275A CO6321135A2 CO 6321135 A2 CO6321135 A2 CO 6321135A2 CO 07109275 A CO07109275 A CO 07109275A CO 07109275 A CO07109275 A CO 07109275A CO 6321135 A2 CO6321135 A2 CO 6321135A2
Authority
CO
Colombia
Prior art keywords
tetrahydrotiopirane
canabinoid
pirazol
modular
syndrome
Prior art date
Application number
CO07109275A
Other languages
English (en)
Inventor
Fina Liotta
Huajun Lu
Mingde Xia
Michael P Wachter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO6321135A2 publication Critical patent/CO6321135A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a un compuesto modulador CB de fórmula (I):o una forma farmacéuticamente aceptable del mismo y un método de uso en el tratamiento, mejora o prevención de un síndrome, trastorno o enfermedad mediado por el receptor CB.
CO07109275A 2005-03-31 2007-10-17 Modulares canabinoides de tetrahidrotiopirano pirazol CO6321135A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66689805P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
CO6321135A2 true CO6321135A2 (es) 2011-09-20

Family

ID=36587178

Family Applications (1)

Application Number Title Priority Date Filing Date
CO07109275A CO6321135A2 (es) 2005-03-31 2007-10-17 Modulares canabinoides de tetrahidrotiopirano pirazol

Country Status (18)

Country Link
US (2) US20060223798A1 (es)
EP (1) EP1863479B1 (es)
JP (1) JP5127697B2 (es)
KR (1) KR20080004559A (es)
CN (1) CN101189007A (es)
AT (1) ATE416768T1 (es)
AU (1) AU2006232945B2 (es)
BR (1) BRPI0609790A2 (es)
CA (1) CA2603104A1 (es)
CO (1) CO6321135A2 (es)
CR (1) CR9479A (es)
DE (1) DE602006004197D1 (es)
EA (1) EA200702130A1 (es)
IL (1) IL186430A0 (es)
MX (1) MX2007012233A (es)
NO (1) NO20075463L (es)
WO (1) WO2006107561A1 (es)
ZA (1) ZA200709342B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101863903B (zh) * 2010-06-08 2014-03-12 沈阳药科大学 1,4-二氢噻吩并[3’,2’:5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof

Also Published As

Publication number Publication date
KR20080004559A (ko) 2008-01-09
JP2008535829A (ja) 2008-09-04
CA2603104A1 (en) 2006-10-12
ZA200709342B (en) 2009-09-30
MX2007012233A (es) 2008-03-18
ATE416768T1 (de) 2008-12-15
AU2006232945B2 (en) 2012-02-23
EP1863479A1 (en) 2007-12-12
JP5127697B2 (ja) 2013-01-23
CR9479A (es) 2008-09-09
IL186430A0 (en) 2008-01-20
NO20075463L (no) 2007-12-21
CN101189007A (zh) 2008-05-28
DE602006004197D1 (de) 2009-01-22
BRPI0609790A2 (pt) 2010-04-27
AU2006232945A1 (en) 2006-10-12
US20060223798A1 (en) 2006-10-05
US20080085899A1 (en) 2008-04-10
WO2006107561A1 (en) 2006-10-12
EA200702130A1 (ru) 2008-04-28
US7524964B2 (en) 2009-04-28
EP1863479B1 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
CL2008003298A1 (es) Forma de dosificacion oral solida que comprende a) un compuesto de accion doble en concentracion entre 4 y 90%, b) un excipiente farmaceuticamente aceptable; proceso de preparación; uso en el tratamiento de enfermedades cardiovasculares y/o renales.
ATE447568T1 (de) Neue pyrinderivate
ECSP066392A (es)
PA8852901A1 (es) Inhibidores de proteina cinasa
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
GEP20125666B (en) HYDROXYMETHYL PYRROLIDINES AS β3 ADRENERGIC RECEPTOR AGONISTS
WO2008127364A3 (en) Antiviral compounds and use thereof
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200942524A (en) Novel aminomethyl benzene derivatives
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
PA8809601A1 (es) Combinación anti-retroviral
EA201100755A1 (ru) Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенной эффективностью по сравнению со стандартным лечением варфарином
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
CY1114933T1 (el) Στερεες φαρμακευτικες συνθεσεις σταθερης δοσης περιεχουσες ιρβεσαρτανη και αμλοδιπινη, η παρασκευη τους και η θεραπευτικη εφαρμογη τους
CR10111A (es) Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido

Legal Events

Date Code Title Description
FA Application withdrawn